Table 1 Demographics
Subject encounters n = 111 | |||
Median age at admission (IQR) | 8.2 | (2.05–13.5) | |
Male | 65 | 58.56% | |
Median length of stay days (IQR) | 13.9 | (8.05–35.9) | |
Primary Admission Diagnosis n, % | |||
Infectious | 56 | 50.45% | |
Respiratory | 39 | 35.14% | |
Hematology/oncology | 26 | 23.42% | |
Cardiology | 17 | 15.32% | |
Gastroenterology | 8 | 7.21% | |
Surgical | 6 | 5.41% | |
Nephrology | 4 | 3.60% | |
Neurology | 1 | 0.90% | |
Comorbidities on Admission n, %a | |||
Immunosuppression | 37 | 33.33% | |
Oncological diagnosis | 25 | 22.52% | |
Central line | 24 | 21.62% | |
Cognitive impairment | 20 | 18.02% | |
Congenital heart disease | 16 | 14.41% | |
Internal hardware | 10 | 9.01% | |
Cerebral palsy/motor delay | 8 | 7.21% | |
Chronic lung disease | 8 | 7.21% | |
Prematurity | 8 | 7.21% | |
Admission to Intensive Care Unit n (%) | 59 | 53.15% | |
Pediatric ICU | 39 | 35.13% | |
Neonatal ICU | 7 | 6.30% | |
Cardiovascular ICU | 19 | 17.12% | |
Hospitalization Complications | |||
Respiratory failure | 75 | 67.57% | |
Operative intervention | 49 | 44.14% | |
Corticosteroids | 49 | 44.14% | |
Vasoactive medications | 39 | 35.14% | |
Immunoglobulin therapy | 20 | 18.02% | |
Death | 8 | 7.21% | |
Acute renal failure | 7 | 6.31% | |
ECMO | 6 | 5.41% | |